Last reviewed · How we verify
XZP-3287+Fulvestrant
XZP-3287+Fulvestrant is a combination of XZP-3287 and Fulvestrant, which works by inhibiting the estrogen receptor.
XZP-3287+Fulvestrant is a combination of XZP-3287 and Fulvestrant, which works by inhibiting the estrogen receptor. Used for Advanced breast cancer.
At a glance
| Generic name | XZP-3287+Fulvestrant |
|---|---|
| Sponsor | Xuanzhu Biopharmaceutical Co., Ltd. |
| Drug class | SERD |
| Target | Estrogen receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Fulvestrant is a selective estrogen receptor degrader (SERD) that binds to the estrogen receptor, promoting its degradation and reducing estrogen signaling. XZP-3287's mechanism is unknown.
Approved indications
- Advanced breast cancer
Common side effects
- Injection site reaction
- Fatigue
- Nausea
Key clinical trials
- A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors (PHASE1, PHASE2)
- A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XZP-3287+Fulvestrant CI brief — competitive landscape report
- XZP-3287+Fulvestrant updates RSS · CI watch RSS
- Xuanzhu Biopharmaceutical Co., Ltd. portfolio CI